Financial Performance - In 2025, the company achieved a revenue of CNY 14.095 billion, representing a year-on-year growth of 14.8% [2] - Adjusted net profit attributable to shareholders was CNY 1.816 billion, up 13.0% year-on-year [2] - The net profit attributable to shareholders decreased by 7.2% to CNY 1.664 billion, primarily due to significant investment gains from the disposal of PROTEOLOGIX shares in 2024 [2] Business Segments - Laboratory services generated revenue of CNY 8.159 billion, with a gross margin of 44.7%, an increase of 0.3 percentage points year-on-year [3] - Small molecule CDMO services reported revenue of CNY 3.483 billion, growing by 16.5%, with a gross margin of 33.8%, up 0.7 percentage points [3] - Clinical research services earned CNY 1.957 billion, reflecting a growth of 7.1% [3] - Large molecule and CGT services achieved revenue of CNY 475 million, also growing by 16.5% [3] Client and Project Growth - The company added over 950 new clients in 2025, bringing the total active clients to over 3,300 [3] - The company participated in 887 global new drug discovery projects, an increase from 2024 [3] - In CMC services, the company was involved in 1,102 projects, including 34 commercial and validation projects, 47 Phase III projects, 271 Phase I/II projects, and 750 preclinical projects [3] Strategic Developments - A strategic cooperation agreement was signed in Q1 2026 with a major international pharmaceutical company for commercial production services of an oral small molecule GLP-1 receptor agonist [3] - The company has established 28 R&D centers and production bases globally, enhancing its integrated R&D and production capabilities [3] Future Outlook - The company expects steady growth in 2026, with new order momentum continuing [4] - Revenue growth in small molecule CDMO services is anticipated to outpace overall company revenue growth, with improved gross margins expected [4] - Clinical research services are projected to maintain growth in 2026 [4]

Group 1: Financial Performance - Revenue reached RMB 14,095 million, with a year-over-year growth of 14.8% [14] - Non-IFRS net profit was RMB 1,816 million, reflecting a year-over-year growth of 13.0% [14] - Net profit declined to RMB 1,664 million, a year-over-year decrease of 7.2% [14] - Revenue from the top 20 multinational corporations (MNCs) grew by 29.4% [14] Group 2: Customer and Market Expansion - Over 950 new customers acquired, totaling over 3,300 active customers, including all top 20 MNCs [15] - Revenue from China entities grew by 15.0%, while overseas subsidiaries saw a growth of 13.8% [21] - New purchase orders (POs) increased by 14% year-over-year [14] Group 3: Operational Highlights - 28 R&D and manufacturing facilities across China, the UK, the US, and Singapore [15] - 887 drug discovery projects currently in progress [16] - 1,397 clinical research organization (CRO) projects, including 125 in Phase III [16] Group 4: Future Outlook - Expected revenue growth of 12-18% year-over-year in 2026 [45] - Continued development of an end-to-end, fully integrated services platform [45] - Focus on advancing the contract development and manufacturing organization (CDMO) business model and integrating AI and automation [45] Group 5: ESG and Sustainability - Achieved an MSCI ESG rating of AA and recognized as a low-risk company by Sustainalytics [23] - Joined the United Nations Global Compact (UNGC) and received the EcoVadis Silver Prize [24]

Core Viewpoint - The company announced a revenue target of 6.67 billion yuan for 2025, representing a year-over-year increase of 14.9%, and a net profit attributable to shareholders of 1.133 billion yuan, up 19.3% year-over-year [1] Group 1: Financial Performance - The company achieved a revenue of 2.04 billion yuan in Q4, reflecting a year-over-year growth of 22.6%, and a constant currency growth of 30.8% [1] - The adjusted net profit attributable to shareholders for 2025 is projected at 1.253 billion yuan, showing a significant year-over-year increase of 56.15% [1] - The overall gross margin for 2025 is expected to be 42%, with the small molecule business maintaining a high gross margin of 46.8% [3] Group 2: Business Segments - Revenue from the small molecule CDMO segment is projected at 4.735 billion yuan, with a year-over-year growth of 3.59% [2] - Emerging businesses are expected to generate 1.929 billion yuan in revenue, marking a substantial year-over-year increase of 57.3%, driven by significant growth in chemical and biological macromolecules [2] - The revenue from chemical macromolecules is anticipated to reach 1.028 billion yuan, with a remarkable year-over-year growth of 123.72% [2] Group 3: Future Guidance - The company expects revenue growth of 19-22% for 2026, indicating a notable acceleration compared to 2025 [2] - The backlog of orders for 2025 is projected at 1.385 billion USD, reflecting a year-over-year increase of 31.65%, with emerging businesses being the main driver [2] - Capital expenditures (CAPEX) are expected to reach 2.1 billion yuan in 2026, representing a year-over-year increase of 65% [2] Group 4: Profitability and Cost Management - The company anticipates further improvement in profitability as emerging businesses expand, with the gross margin for emerging businesses expected to rise to 30.1%, an increase of 8.4 percentage points [3] - The operating expense ratio is projected to decrease slightly to 22.53% in 2025, down 0.77 percentage points year-over-year [3] - The company forecasts net profits of 1.448 billion yuan, 1.939 billion yuan, and 2.503 billion yuan for 2026, 2027, and 2028, respectively, with year-over-year growth rates of 27.82%, 33.92%, and 29.13% [3]

Group 1: Company Overview and Growth Prospects - Kailaiying Pharmaceutical Group is focusing on expanding its peptide business, which is currently the fastest-growing segment, with 19 clinical projects in the GLP-1, Amylin, and cyclic peptide areas, 8 of which are in late-stage clinical trials [2][3] - The company has seen significant growth and structural changes in its service pipeline over the past two years, with over 50 peptide projects extending beyond weight loss to autoimmune and other fields [3] Group 2: Production Capacity and Capital Expenditure - The small molecule business is operating at high capacity, with the TJ3 plant expected to alleviate API capacity constraints by Q2 2026 [4] - The total capital expenditure plan for 2026 is approximately RMB 2.1 billion, with 70%-80% allocated to emerging business segments, particularly in chemical and biological macromolecules [4] Group 3: Revenue and Profitability Outlook - The company anticipates a revenue growth of 19%-22% for 2026, with a potential 2-3 percentage point increase under constant exchange rates [5] - Emerging business segments are expected to see continuous improvement in gross margins due to factors such as increased overseas revenue share and enhanced capacity utilization [5] Group 4: Order Growth and Market Demand - As of the end of Q1 2026, the total order backlog is USD 1.385 billion, reflecting a 31.65% year-over-year increase, driven by sustained growth in small molecule commercialization projects [6][8] - The demand for new molecular types, such as conjugated drugs and peptides, is robust, with a notable scarcity in production capacity [7] Group 5: Strategic Initiatives and Challenges - The company is actively managing cost impacts from rising chemical prices due to geopolitical tensions, with proactive procurement strategies in place [5] - There is ongoing exploration of overseas capacity expansion, aligned with business development efforts, although the pace remains cautious [6]

Investment Rating - The investment rating for the company is "Buy" [3] Core Insights - The company has achieved a revenue of 5.94 billion yuan in 2025, representing a year-on-year growth of 46.7%, with an adjusted net profit of 1.56 billion yuan, up 69.9% [2] - The company is expected to maintain high growth in the coming years due to strong order growth and capacity expansion [2] - The company signed 70 new iCMC projects in 2025, with a total order backlog of 1.49 billion USD, reflecting a 50.3% year-on-year increase [2] - The company plans to invest 8 billion yuan in capital expenditures from 2026 to 2030 to enhance production capacity [2] - The company aims for a compound annual growth rate (CAGR) of 30% to 35% from 2025 to 2030, exceeding the industry average of 25.6% [8] Financial Summary - In 2025, the company reported total revenue of 5.94 billion yuan, with a year-on-year growth of 46.69% [11] - The adjusted net profit for 2025 was 1.48 billion yuan, with a year-on-year increase of 38.41% [11] - The projected revenue for 2026 is 8.20 billion yuan, with a year-on-year growth of 37.89% [11] - The projected earnings per share (EPS) for 2026 is 1.69 yuan, with a PE ratio of 29.74 [9][11]

Summary of WuXi AppTec Conference Call Company Overview - **Company**: WuXi AppTec - **Industry**: Contract Research, Development, and Manufacturing Organization (CRDMO) Key Financial Guidance - **2026 Revenue Guidance**: Expected to be between 51.3 billion and 53 billion RMB, with a constant currency growth rate of 22%-26% [2][3] - **Backlog Orders**: As of the end of 2025, backlog orders reached 58 billion RMB, representing a year-on-year increase of 28.8%, and a 34% increase when excluding currency effects [2][3] - **Order Conversion Rate**: Anticipated to be around 70% over the next 12 months, indicating improved business visibility [2][12] Business Segments Performance - **TIDES Business (Peptides/Nucleic Acids)**: Expected to exceed 10 billion RMB in revenue by 2025, with a projected growth of 30%-40% in 2026 when excluding currency effects [2][5] - **Small Molecule CDMO**: Expected to recover to double-digit growth in 2025, with acceleration anticipated in 2026 [2][11] - **Testing and Biology Segments**: Both segments achieved double-digit growth, reflecting a recovery in early-stage research financing [2][11] Capital Expenditure - **2026 Capital Expenditure Guidance**: Expected to be between 6.5 billion and 7.5 billion RMB, primarily focused on expanding global capacity for small molecules and new molecules [2][15] Profitability Insights - **Adjusted Net Profit Margin**: Reached approximately 35% in Q4 2025, with expectations to remain stable and resilient in 2026 [2][5] - **Inventory Levels**: Increased to 9 billion RMB, driven by the need to support later-stage and commercial projects [2][9] Market Dynamics - **Raw Material Costs**: Rising oil prices may impact chemical raw material costs, which account for 40%-50% of CDMO operating costs [4] - **Global R&D Financing**: Observed recovery in early-stage R&D financing, with positive trends in order volume and customer inquiries [6][11] Regulatory and Governance - **1,260H List Concerns**: Company emphasizes transparency and governance, asserting no government or military affiliations, and plans to address any misunderstandings [2][13][14] Competitive Landscape - **Foreign Investment in China**: Notable investments from multinational corporations (MNCs) in China, indicating a trend towards localized supply chains [10][18] Future Outlook - **2026 Revenue Growth**: Expected growth of 18%-22%, with a focus on maintaining a stable order-to-revenue conversion rate [3][12] - **AI Integration**: Company is leveraging AI to enhance operational efficiency and industry insights, which is expected to positively impact profitability [20] Conclusion - WuXi AppTec is positioned for robust growth in 2026, driven by strong order backlogs, strategic capital investments, and a focus on high-margin business segments. The company is navigating market challenges while maintaining a commitment to transparency and operational excellence.

Investment Rating - The report maintains a "Buy" rating for WuXi XDC [4][17]. Core Insights - WuXi XDC reported a revenue of RMB 5.94 billion for 2025, representing a year-on-year growth of 46.7%, and a net profit of RMB 1.48 billion, up 38.4% year-on-year. The adjusted net profit reached RMB 1.56 billion, reflecting a 70.0% increase, aligning with expectations [7][13]. - The company experienced significant growth in overseas revenue, with North America and Europe revenues increasing by 49% and 129% year-on-year, respectively, contributing to 76% of total revenue [8][14]. - The total backlog of orders grew by 50.3% year-on-year to USD 1.5 billion, with the cumulative number of customers increasing from 499 in 2024 to 643 in 2025 [9][15]. - WuXi XDC is expanding its production capacity through strategic acquisitions, including the acquisition of BioDlink, which is expected to enhance its production capabilities and customer base [10][16]. Financial Data and Earnings Forecast - The projected revenue for WuXi XDC is expected to reach RMB 8.06 billion in 2026, with a year-on-year growth rate of 35.64% [11][19]. - The adjusted earnings per share (EPS) forecast for 2026 has been raised from RMB 1.68 to RMB 1.69, with further increases projected for 2027 and 2028 [17].

WuXi AppTec 2025 Annual Results March 24, 2026 1 Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends", or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and informa ...

Core Viewpoint - Pharmaron has entered a significant partnership with Eli Lilly to commercialize the small molecule oral GLP-1 drug Orforglipron, with Eli Lilly investing $200 million to enhance Pharmaron's production capacity, indicating a strategic shift in the competitive landscape of oral GLP-1 drugs in China [1][2]. Group 1: Partnership and Investment - Eli Lilly's investment of $200 million in Pharmaron is aimed at establishing local production capabilities for Orforglipron, which has already submitted a market application in China [1]. - The collaboration is notable as Eli Lilly chose Pharmaron over its existing major CDMO supplier, WuXi AppTec, suggesting a strategic pivot in its supply chain [1][2]. Group 2: Company Background and Business Model - Pharmaron, founded in 2004, has primarily focused on preclinical CRO development, with a smaller proportion of its business in CDMO, contrasting with WuXi AppTec's integrated model [1][2]. - As of 2024, Pharmaron's revenue composition shows 57% from laboratory services, 24% from small molecule CDMO, and 15% from clinical services, indicating a less diversified revenue stream compared to competitors [2][4]. Group 3: Market Context and Competitive Landscape - The rising labor costs in China have impacted the profitability of traditional laboratory services, with Pharmaron's net profit margin at 11.5%, significantly lower than WuXi AppTec's 24% [4]. - The investment trend among foreign pharmaceutical companies in Beijing, including AstraZeneca and Sanofi, highlights a growing focus on the region for production and R&D capabilities [4][6]. Group 4: Future Prospects - Pharmaron's collaboration with Eli Lilly positions it to potentially secure stable revenue growth in the oral GLP-1 market, although its current CDMO capabilities are not as robust as those of its competitors [6]. - The new production base for large molecules and CGT in Ningbo is expected to contribute to future growth, although its current output remains low [6].

Core Viewpoint - WuXi AppTec (02268) has seen a significant stock price increase following its positive earnings forecast for 2025, indicating strong growth potential in the XDC CRDMO industry driven by rising demand for integrated services and CMC orders [2][5]. Company Summary - WuXi AppTec's stock price rose by 7.54% to HKD 62.75, with a trading volume of HKD 301 million [2][5]. - The company issued an earnings forecast for 2025, leading to a slight downward adjustment in revenue and adjusted net profit projections for 2025-2027 by 1-3%, estimating revenues of RMB 5.88 billion, 8.28 billion, and 11.11 billion, and adjusted net profits of RMB 1.60 billion, 2.45 billion, and 3.42 billion respectively, corresponding to a CAGR of 38% and 46% for 2025-2027 [2][5]. Industry Summary - In the first two months of 2026, there were 25 financing events in the global XDC sector, a significant increase from 18 events in the same period of 2025, indicating a growing trend in investment activity [2][5]. - The number of BD transactions for XDC candidate drugs has remained stable, with a substantial increase in total upfront payments, reflecting a robust market environment [2][5]. - Since the beginning of 2024, there has been a gradual increase in the number of financing events, BD transactions, and upfront payment totals in the XDC field, suggesting a sustained demand improvement in the CRDMO industry [2][5].